Cancer Center Core Support Grant

$4,587,184P30FY2008CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Paper 39710854 Paper 39677814 Paper 39677813 Paper 39589879 Paper 39554138 Paper 39554127 Paper 39484366 Paper 39386450 Paper 39325056 Paper 39294048 Paper 39282325 Paper 39272889 Paper 39228741 Paper 39169899 Paper 39158404 Paper 38982561 Paper 38968117 Paper 38839950 Paper 38771648 Paper 38723698 Paper 38719809 Paper 38713004 Paper 38626853 Paper 38585946 Paper 38518770 Paper 38511933 Paper 38464266 Paper 38412093 Paper 38370678 Paper 38354231 Paper 38341660 Paper 38341658 Paper 38325563 Paper 38270802 Paper 38181796 Paper 38082117 Paper 38059331 Paper 38048400 Paper 38045310 Paper 37919520 Paper 37902809 Paper 37871333 Paper 37812335 Paper 37809067 Paper 37803324 Paper 37801341 Paper 37762169 Paper 37754663 Paper 37730274 Paper 37655659 Paper 37559183 Paper 37520728 Paper 37482512 Paper 37435085 Paper 37398351 Paper 37366057 Paper 37357983 Paper 37353093 Paper 37333286 Paper 37333052 Paper 37322036 Paper 37294422 Paper 37292767 Paper 37289038 Paper 37280220 Paper 37260544 Paper 37214856 Paper 37196065 Paper 37192158 Paper 37179121 Paper 37160922 Paper 37156551 Paper 37152809 Paper 37140454 Paper 37128507 Paper 37126232 Paper 37094160 Paper 37086408 Paper 37083641 Paper 37069149 Paper 37066394 Paper 37064017 Paper 37053013 Paper 37037616 Paper 37000164 Paper 36980702 Paper 36971339 Paper 36948187 Paper 36930646 Paper 36929731 Paper 36923158 Paper 36922590 Paper 36906850 Paper 36890230 Paper 36884217 Paper 36880064 Paper 36876496 Paper 36860908 Paper 36856617 Paper 36795805

Abstract

This is a five-year CCSG renewal (years 29-34) for the 231-member Jonsson Comprehensive Cancer Center at UCLA. Over the past five years,there have been extensivechanges, including strengthening the leadership of the Program Areas with new appointments. The Division of Basic Sciences has added the recentlyformed Gene RegulationProgramArea, and nowconsistsoffive ProgramAreas: 1) Signal Transduction;2) Molecular, Cellular& Developmental Biology;3) Tumor Immunology;4) Viral & Chemical Carcinogenesis;and 5) Gene Regulation. The Divisionof Cancer Prevention& ControlResearch has substantiallystrengthened itstwo ProgramAreas: 1) Healthy&At-Risk Populations;and 2) Patients& Survivors. The Divisionof Clinical/TranslationalResearch has added the former developmentalprogram area, Genitourinary Oncology (formerly Prostate Oncology),and now consistsof four ProgramAreas: 1) Women's Cancers; 2) HematopoieticMalignancies& Bone MarrowTransplantation;3) Genitourinary Oncology;and 4) Cancer Therapy Development(formerlySolidTumorOncology). New Shared Resources are proposed,including Gene Expression Core, Immunology, Tissue Array, Bioinformatics,Mass Spectrometry & Proteomics,Small Animal Imaging, and Family& Genetic Evaluation. This gives a total of 14 Shared Resources,including those continuing from the previous funding period, Flow Cytometry, Nude/SCID Mouse, Media Prep, TransgenicMouse/EmbryonicStem Cell, Human Tissue Research Center, the BASE Unit, and the ClinicalResearch Unit. Significantresearchaccomplishmentsoverthe past f_lndingcycle includeour participationin the FDA approval of Herceptinand Gleevec. Cancer focusha_ been strengthened considerably,as evidenced by a doublingof the ratio of NCI dollarsto number of JCCC_members. The number of patientsenrolledon cancer therapeutic trials has increased to 5,335 overthe pasttfive years, from 3,348 duringthe previousfunding cycle. Finally, $5,594,251 in new cancer programawards has been receivedduringthe past 18 months, including an "In Vivo Imaging Center" grant, a Director'sChallenge Award, and a Lung SPORE.

View original record on NIH RePORTER →